A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders

NCT00236444 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit and Disruptive Behavior Disorders

Interventions

DRUG: risperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.